FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
Blood-based measurement of neurofilament light chain provides compelling evidence to support an accelerated drug approval by the FDA. The decision has positive implications for NfL blood testing as... | June 18, 2023
Source: marketscreener.com